Compared with human soluble insulin, the rapid-acting analogs were developed to accelerate insulin absorption, and simultaneously minimize postprandial glucose rise more effectively and lower the risk of hypoglycemia due to the high exogenous insulin concentrations for longer needed (Senior and Hramiak, 2019). This evidence concerns the gene INS and Hypoglycemia.